sibutramine has been researched along with Sleep Apnea, Obstructive in 6 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)
| Excerpt | Relevance | Reference |
|---|---|---|
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 7.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 5.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| "The aim of the present study was to compare the efficacy of 1 yr of sibutramine-induced weight loss versus continuous positive airway pressure (CPAP) treatment on sleep-disordered breathing, cardiac autonomic function and systemic blood pressure in obese patients with obstructive sleep apnoea." | 5.14 | Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. ( Ferland, A; Poirier, P; Sériès, F, 2009) |
| "6-month open-label weight loss trial combining sibutramine (a serotonin and noradrenaline reuptake inhibitor) with a 600-kcal deficit diet and exercise." | 3.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "We screened male, symptomatic OSAHS patients who presented consecutively at the sleep clinic." | 2.71 | Sibutramine does not worsen sleep apnea syndrome: a randomized double-blind placebo-controlled study. ( Basile, BR; Martinez, D, 2005) |
| "Obesity is frequently associated with other pathologies: cardiovascular, oncologic, systemic (diabetes) or oral." | 1.35 | [Obesity and oral health: risk factors of obese patients in dental practice]. ( Godlewski, AE; Nicolas, E; Veyrune, JL, 2008) |
| "Sibutramine has been increasingly used in the management of obesity, but is relatively contraindicated in patients with hypertension." | 1.34 | The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. ( Banerjee, D; Caterson, I; Grunstein, RR; Hedner, JA; Phillips, CL; Yee, BJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Godlewski, AE | 1 |
| Veyrune, JL | 1 |
| Nicolas, E | 1 |
| Ferland, A | 1 |
| Poirier, P | 1 |
| Sériès, F | 1 |
| Phillips, CL | 2 |
| Yee, BJ | 2 |
| Trenell, MI | 1 |
| Magnussen, JS | 1 |
| Wang, D | 1 |
| Banerjee, D | 2 |
| Berend, N | 1 |
| Grunstein, RR | 2 |
| Martinez, D | 1 |
| Basile, BR | 1 |
| Caterson, I | 1 |
| Hedner, JA | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea[NCT00729963] | Phase 4 | 45 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sibutramine and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
2 trials available for sibutramine and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Mass Index; Continuous Positive Airway Pressure; C | 2009 |
Sibutramine does not worsen sleep apnea syndrome: a randomized double-blind placebo-controlled study.
Topics: Adult; Appetite Depressants; Blood Pressure; Cyclobutanes; Double-Blind Method; Heart Rate; Humans; | 2005 |
3 other studies available for sibutramine and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
[Obesity and oral health: risk factors of obese patients in dental practice].
Topics: Adult; Appetite Depressants; Child; Child, Preschool; Cyclobutanes; Dental Caries; Diabetes Mellitus | 2008 |
Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Appetite Depressants; Biomarkers; Cardiovascular Diseases; C | 2009 |
The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
Topics: Adult; Aged; Appetite Depressants; Blood Pressure; Cohort Studies; Cyclobutanes; Heart Rate; Humans; | 2007 |